Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd > Government Funding. Did you guys miss this part

<< Previous

Bullboard Posts

Next >>

Comment by kevlin139on May 30, 2020 7:44pm

61 Views

Post# 31092593

RE:Government Funding. Did you guys miss this part

what we missed was the news release by the company didnt they think it was news worthy, material change?

Valuehunter72 wrote:

Grant, Contribution or Other Financial Benefit

Seeking funding from the Strategic Innovation Fund to support COVID-19 vaccine and therapy clinical trials

clearly states what it is for and not from previous years.

Link here Click to see Covid funding details for VXL